医学
随机对照试验
麻醉
随机化
血压
平均动脉压
择期手术
外科
血流动力学
心率
内科学
作者
J.M. Calvo Vecino,Javier Ripollés‐Melchor,Monty Mythen,R. Casans‐Francés,Ahmet A. Balık,Julián Artacho,Eugenio Martínez Hurtado,Ana Serrano Romero,Cristina Fernández,Steffen Lis,Ana Tirado Errazquin,Cristina Gil Lapetra,Ane Abad‐Motos,Elena Garrido,Cristina Medrano Viñas,Raúl Villaba,Pilar Cobeta,Eva Ureta,M Rigabert Montiel,Nuria Mané
标识
DOI:10.1016/j.bja.2017.12.018
摘要
BackgroundThe aim of this study was to evaluate postoperative complications in patients having major elective surgery using oesophageal Doppler monitor-guided goal-directed haemodynamic therapy (GDHT), in which administration of fluids, inotropes, and vasopressors was guided by stroke volume, mean arterial pressure, and cardiac index.MethodsThe FEDORA trial was a prospective, multicentre, randomised, parallel-group, controlled patient- and observer-blind trial conducted in adults scheduled for major elective surgery. Randomization and allocation were carried out by a central computer system. In the control group, intraoperative fluids were given based on traditional principles. In the GDHT group, the intraoperative goals were to maintain a maximal stroke volume, with mean arterial pressure >70 mm Hg, and cardiac index ≥2.5 litres min−1 m−2. The primary outcome was percentage of patients with moderate or severe postoperative complications during the first 180 days after surgery.ResultsIn total, 450 patients were randomized to the GDHT group (n=224) or control group (n=226). Data from 420 subjects were analysed. There were significantly fewer with complications in the GDHT group (8.6% vs 16.6%, P=0.018). There were also fewer complications (acute kidney disease, pulmonary oedema, respiratory distress syndrome, wound infections, etc.), and length of hospital stay was shorter in the GDHT group. There was no significant difference in mortality between groups.ConclusionsOesophageal Doppler monitor-guided GDHT reduced postoperative complications and hospital length of stay in low–moderate risk patients undergoing intermediate risk surgery, with no difference in mortality at 180 days.Clinical trial registrationISRCTN93543537.
科研通智能强力驱动
Strongly Powered by AbleSci AI